Health Care [ 3/12 ] | Pharmaceuticals [ 37/74 ]
NASDAQ | Common Stock
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases.
The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder.
Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose.
The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023.
The company is headquartered in San Diego, California.
On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in theU. S.
Bankruptcy Court for the District of Delaware.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 23 | -0.20 Decreased by -554.67% | - |
| Aug 21, 23 | -3.34 Decreased by -5.46 K% | - |
| May 15, 23 | -0.06 Increased by +14.29% | - |
| Mar 16, 23 | -0.02 Increased by +60.00% | -0.02 |
| Nov 14, 22 | -0.03 Increased by +62.50% | -0.03 |
| Aug 10, 22 | -0.06 Decreased by -50.00% | -0.04 Decreased by -71.43% |
| May 17, 22 | -0.07 Increased by +72.55% | -0.03 Decreased by -133.33% |
| Mar 31, 22 | -0.05 Increased by +50.00% | -0.04 Decreased by -11.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 9.06 K Decreased by -99.40% | -1.39 M Increased by +68.45% | Decreased by -15.32 K% Decreased by -5.14 K% |
| Jun 30, 23 | 6.95 K Decreased by -82.57% | -8.57 M Decreased by -2.11% | Decreased by -123.46 K% Decreased by -485.84% |
| Mar 31, 23 | 1.45 M - | -8.94 M - | Decreased by -615.48% - |
| Dec 31, 22 | 2.15 M - | -3.33 M - | Decreased by -154.72% - |
| Sep 30, 22 | 1.51 M - | -4.40 M - | Decreased by -292.15% - |
| Jun 30, 22 | 39.85 K - | -8.40 M - | Decreased by -21.07 K% - |